PM(NOC) Proceedings:
- JUBLIA (efinaconazole): Bausch Health and Valeant Canada v Pharmascience
- KUVAN (sapropterin dihydrochloride): BioMarin Pharmaceutical v Teva Canada
- JANUMET (sitagliptin and metformin hydrochloride): Merck v Pharmascience and "Company X"
- JARDIANCE (empagliflozin): Boehringer Ingelheim v JAMP Pharma
- IMBRUVICA (ibrutinib): Pharmacyclics and Janssen v Natco Pharma (Canada)
- FORXIGA (dapagliflozin): AstraZeneca v Pharmascience
Others:
- JANUMET (sitagliptin and metformin hydrochloride): Merck v Pharmascience and "Company X"
For complete details about these proceedings, click here.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.